Updates in the Prevention and Treatment of Recurrent Clostridioides difficile Infection Focus on High-Risk Populations

Sign Up For Updates

Preventing and Treating Recurrent Clostridioides difficile Infection in High-Risk Populations:
A Pro/Con Debate
A Virtual Midday Symposium conducted at the 2020 ASHP Midyear Clinical Meeting and Exhibition
(Midyear registration not required)

Tuesday, December 8, 2020
1:00 - 2:30 p.m. ET

Register Download Handout
Available at least 24 hours before webinar.

Overview

This 1.5-hour interprofessional educational activity uses a point-counterpoint approach to decision making for managing special patient populations at high-risk for poor outcomes also taking into account cost-benefit considerations.


Target Audience

The target audience is physicians, pharmacists, physician assistants, nurse practitioners who care for patients at risk for recurrent Clostridioides difficile Infection.

Format

This activity features slide presentations, active learning, and questions/discussion with faculty. 


Learning Objectives
  • Distinguish how current Clostridioides difficile infection (CDI) therapies prevent CDI recurrence.
  • Identify patients that would benefit from fidaxomicin or vancomycin with another anti-CDI recurrence strategy.
  • Identify patient populations in which an anti-CDI recurrence strategy would be most cost effective in practice.
  • Develop an interprofessional treatment plan for recurrent CDI for special populations.
     
Like your favorites to provide us feedback!

Faculty
Anne J. Gonzales-Luna, Pharm.D., BCIDP
Assistant Professor
Department of Pharmacy Practice and Translational Research
The University of Houston College of Pharmacy
Houston, Texas
Andrew Skinner, M.D.
Division of Infectious Diseases,
Loyola University Medical Center
Clinical Instructor,
Loyola University Chicago Stritch School of Medicine

Kevin W. Garey, Pharm.D., M.S., FASHP, Activity Chair
Professor and Chair
University of Houston College of Pharmacy
Houston, Texas
Krishna Rao, M.D., M.S.
Assistant Professor
University of Michigan
Ann Arbor, Michigan
Erik R. Dubberke, M.D., MSPH
Professor of Medicine
Clinical Director, Transplant Infectious Diseases
Washington University School of Medicine
St. Louis, Missouri


Agenda

1:00 p.m.
Welcome and Introductions
Kevin W. Garey, Pharm.D., M.S., FASHP, Activity Chair

1:05 p.m.
Vancomycin is still commonly used but causes dysbiosis and a high recurrence rate.
Moderator: Erik R. Dubberke, M.D., MSPH
Can vancomycin be used as part of an anti-CDI recurrence strategy?
Krishna Rao, M.D., M.S.
Kevin W. Garey, Pharm.D., M.S., FASHP

1:30 p.m.
What are the currently available anti-recurrence strategies?
Moderator: Kevin W. Garey, Pharm.D., M.S., FASHP
What is the best anti-CDI recurrence strategy?
Erik R. Dubberke, M.D., MSPH
Krishna Rao, M.D., M.S.

1:55 p.m.
Choosing an anti-CDI recurrence strategy reduced recurrence but has higher drug acquisition costs.  
Moderator:  Krishna Rao, M.D., M.S.
When is an anti-CDI recurrence strategy cost-effective?
Erik R. Dubberke, M.D., MSPH
Kevin W. Garey, Pharm.D., M.S., FASHP

2:20 p.m. ET
Faculty Discussion/Questions and Answers


CPE Information

The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

 

ACPE #: 0204-0000-20-438-L01-P
Activity Type: Application-based
CE Credits: 1.5
Activity Fee: Free of charge


CME Information

The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The American Society of Health-System Pharmacists designates this internet live course for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Process CE by February 1, 2021

Claim CE (enter the CE code announced during activity and complete the evaluation).

Verify credit has posted to your ​NABP eProfile account before the 60-day deadline.

After ACPE's 60-day deadline, ASHP will no longer be able to report credits.


Join the Live Broadcast

Join the live interactive webinar using your computer or smart device. 

Watch for a confirmation email with additional instructions. 

Get the app and view system requirements

Go To Webinar